natgillin/translations-raw huggingface dataset:
Humalog Mix25 KwikPen er en erstatning for dit eget insulin og bruges til at kontrol- lere dit blodsukker på langt sigt.
Humalog Mix25 is a substitute for your own insulin and is used to control glucose in the long term.
Humalog Mix25 KwikPen er en færdig- blandet suspension.
It is a premixed suspension.
Humalog Mix25 NPL
Hypoglycaemic activity
Humalog Mix25 NPL
Liprolog Mix25 Liprolog Basal
Humalog Mix25 opbevares i et køleskab (2 ºC – 8 ºC), indtil det tages i brug for første gang.
Before the first use store your Humalog Mix25 in a refrigerator (2C – 8C).
Humalog Mix25 opbevares i køleskab (2 ºC – 8 ºC), indtil det tages i brug for første gang.
Before the first use store your Humalog Mix25 in a refrigerator (2C – 8C).
Humalog Mix25: 25 % insulin lispro-opløsning og 75 % insulin lispro protamin-suspension
Humalog Mix25: 25% insulin lispro solution and 75% insulin lispro protamine suspension;
Humalog Mix50 100 E/ml injektionsvæske, suspension i cylinderampul indeholder:
What Humalog Mix50 100 U/ml suspension for injection in cartridge contains
Humalog Mix50 100 E/ml injektionsvæske, suspension i cylinderampul Insulin lispro
Humalog Mix50 100 U/ml suspension for injection in cartridge insulin lispro
Humalog Mix50 100 E/ml injektionsvæske, suspension i cylinderampul.
Humalog Mix50 100 U/ml suspension for injection in cartridge
Humalog Mix50 100 E/ml injektionsvæske, suspension i hætteglas
Humalog Mix50 100 U/ml suspension for injection in vial
Humalog Mix50 100 E/ml injektionsvæske, suspension i hætteglas indeholder:
What Humalog Mix50 100 U/ml suspension for injection in vial contains
Humalog Mix50 100 E/ml injektionsvæske, suspension i hætteglas Insulin lispro
Humalog Mix50 100 U/ml suspension for injection in vial insulin lispro
Humalog Mix50 100 E/ml KwikPen injektionsvæske, suspension
Humalog Mix50 100 U/ml KwikPen, suspension for injection
Humalog Mix50 100 E/ml KwikPen injektionsvæske, suspension indeholder:
What Humalog Mix50 100 U/ml KwikPen, suspension for injection contains
Humalog Mix50 100 E/ml KwikPen injektionsvæske, suspension Insulin lispro
Humalog Mix50 100 U/ml KwikPen, suspension for injection insulin lispro
Humalog Mix50 100 E/ml KwikPen injektionsvæske, suspension.
Humalog Mix50 100 U/ml KwikPen, suspension for injection
Humalog Mix50 100 E/ml KwikPen, injektionsvæske, suspension 50% insulin lispro og 50% insulin lispro protaminsuspension Subkutan anvendelse
Humalog Mix50 100 U/ml KwikPen, suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Humalog Mix50 100 E/ml KwikPen, injektionsvæske, suspension er en steril hvid suspension og indeholder 100 enheder insulin lispro per milliliter (100 E/ml) injektionsvæske.
Humalog Mix50 100 U/ml KwikPen, suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 U/ml) suspension for injection.
Humalog Mix50 100 E/ml KwikPen, injektionsvæske, suspension, fremstilles af:
Humalog Mix50 100 U/ml KwikPen, suspension for injection is made by:
Humalog Mix50 100 E/ml KwikPen, injektionsvæske, suspension.
Humalog Mix50 100 U/ml KwikPen, suspension for injection
Humalog Mix50 100 E/ml, injektionsvæske, suspension er en steril hvid suspension og indeholder 100 enheder insulin lispro per milliliter (100 E/ml) injektionsvæske.
Humalog Mix50 100 U/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 U/ml) suspension for injection.
Humalog Mix50 100 E/ml, injektionsvæske, suspension, i cylinderampul fremstilles af:
Humalog Mix50 100 U/ml suspension for injection in cartridge is made by:
Humalog Mix50 100 E/ml, injektionsvæske, suspension, i hætteglas findes i pakninger med 1 hætteglas.
Humalog Mix50 100 U/ml suspension for injection in vial comes in a pack of 1 vial.
Humalog Mix50 100 E/ml, injektionsvæske, suspension, i hætteglas fremstilles af:
Humalog Mix50 100 U/ml suspension for injection in vial is made by:
Humalog Mix50 cylinderampuller er beregnet til at blive brugt sammen med en CE mærket pen, som anbefalet i brugsanvisningen fra fremstilleren af pennen.
Humalog Mix50 cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Humalog Mix50 er en hvid, steril suspension.
Humalog Mix50 is a white sterile suspension.
Humalog Mix50 er en hvid, steril suspension.
Humalog Mix50 is a white, sterile suspension.
Humalog Mix50 kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Humalog Mix50 can cause side effects, although not everybody gets them.
Humalog Mix50 KwikPen er en erstatning for dit eget insulin og bruges til at kontrollere dit blodsukker på langt sigt.
Humalog Mix50 is a substitute for your own insulin and is used to control glucose in the long term.
Humalog Mix50 KwikPen er en færdig- blandet suspension.
It is a premixed suspension.
Humalog Mix50 NPL
Hypoglycaemic activity
Humalog Mix50 opbevares i køleskab (2 ºC – 8 ºC), indtil det tages i brug for første gang.
Before the first use store your Humalog Mix50 in a refrigerator (2C – 8C).
Humalog Mix50: 50 % insulin lispro-opløsning og 50 % insulin lispro protamin-suspension.
Humalog Mix50: 50% insulin lispro solution and 50% insulin lispro protamine suspension.
Humalog må ikke anvendes, hvis insulinet virker uklart, tyktflydende, er let farvet, eller hvis der ses småpartikler i væsken.
Humalog should not be used if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Humalog må kun bruges i den fyldte pen.
Humalog should not be used outside of the prefilled pen device
Humalog må kun bruges i den fyldte pen.
Liprolog should not be used outside of the pre-filled pen device
Humalog må kun bruges i med den fyldte pen.
Humalog should not be used outside of the prefilled pen device
Humalog må kun bruges i med den fyldte pen.
Liprolog should not be used outside of the pre-filled pen device
Humalog opbevares i køleskab (2 ºC – 8 ºC), indtil det tages i brug for første gang.
Before the first use store your Humalog in a refrigerator (2C – 8C).
Humalog opløsningen bør være klar og farveløs.
The Humalog solution should be clear and colourless.
Humalog Pen bør ikke blandes med insulinpræparater fremstillet af andre producenter eller med animalske insulinpræparater.
Humalog preparations should not be mixed with insulins produced by other manufacturers or with animal insulin preparations.
Humalog- serien omfatter hurtigtvirkende insulinopløsninger (Humalog), længerevirkende insulinsuspensioner (Humalog Basal) og kombinationer af disse to i forskellige blandingsforhold (Humalog Mix):
The Humalog range comprises fast-acting insulin solutions (Humalog), longer-acting insulin suspensions (Humalog Basal), and combinations of both in various proportions (Humalog Mix):
Humalog: insulin lispro-opløsning, der fås i en standardstyrke eller en højere styrke (100 eller 200 enheder/ml)
Humalog: insulin lispro solution, available in a standard or a higher strength (100 or 200 units/ml);
Humalog® 200 enheder/ml injektionsvæske, opløsning i fyldt pen insulin lispro
Humalog 200 units/ml solution for injection in pre-filled pen insulin lispro
Human alfa-1- proteinasehæmmer har en molekylvægt på 51 kDa og tilhører familien serinproteasehæmmere.
Human alpha1-proteinase inhibitor has a molecular weight of 51 kDa and belongs to the family of serine protease inhibitors.
Human alfa-1-proteinasehæmmer
Human alpha1-proteinase inhibitor
Human alfa-1-proteinasehæmmer 1000 mg
Human alpha1-proteinase inhibitor 1,000 mg
Human fremstilles med rekombinant DNA-teknologi i Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Human insulin
Insulin human
Human insulin * 40 IE som protaminzink insulin.
Insulin human* 40 IU as protamine zinc insulin.
Human insulin 25 fremstilles med rekombinant DNA-teknologi i Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Human insulin* 40 IE som protaminzink insulin.
Insulin human* 40 IU as protamine zinc insulin.
Human koagulationsfaktor VIII udvindes ikke af humant plasma, men produceres via en metode, der kaldes ”rekombinant dna-teknologi”: Det fremstilles af en celle, som har modtaget et gen (dna), der sætter det i stand til at producere human koagulationsfaktor VIII.
The human coagulation factor VIII is not extracted from human plasma but produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Human koagulationsfaktor X er stort set fastholdt i det vaskulære rum: den tilsyneladende gennemsnitlige fordelingsvolumen (Vss) var 56,3 (24,0) ml/kg.
Human coagulation factor X is largely retained within the vascular compartment: mean apparent volume of distribution (Vss) was 56.3 (24.0) mL/kg.
Human papillomavirus1 type 6 L1 protein2,3 20 mikrogram Human papillomavirus1 type 11 L1 protein2,3 40 mikrogram Human papillomavirus1 type 16 L1 protein2,3 40 mikrogram Human papillomavirus1 type 18 L1 protein2,3 20 mikrogram
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms.
Human papillomavirus1 type 6 L1 protein2,3 30 mikrogram Human papillomavirus1 type 11 L1 protein2,3 40 mikrogram Human papillomavirus1 type 16 L1 protein2,3 60 mikrogram Human papillomavirus1 type 18 L1 protein2,3 40 mikrogram Human papillomavirus1 type 31 L1 protein2,3 20 mikrogram Human papillomavirus1 type 33 L1 protein2,3 20 mikrogram Human papillomavirus1 type 45 L1 protein2,3 20 mikrogram Human papillomavirus1 type 52 L1 protein2,3 20 mikrogram Human papillomavirus1 type 58 L1 protein2,3 20 mikrogram
Human Papillomavirus1 Type 6 L1 protein2,3 30 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 60 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 31 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 33 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 45 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 52 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 58 L1 protein2,3 20 micrograms
Human Papillomavirus1 type 6 L1-protein2,3 20 mikrogram Human Papillomavirus1 type 11 L1-protein2,3 40 mikrogram Human Papillomavirus1 type 16 L1-protein2,3 40 mikrogram Human Papillomavirus1 type 18 L1 protein2,3 20 mikrogram
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms
Human papillomavirusvaccine [type 6, 11, 16, 18] (rekombinant, )
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
Human papillomavirusvaccine [type 6, 11, 16, 18] (rekombinant, adsorberet)
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)
Human papillomavirusvaccine, 9-valent (rekombinant, adsorberet)
Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Human papillomvirusvaccine [type 16, 18] (rekombinant, adjuveret, adsorberet)
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)
Human papillomvirusvaccine [type 16, 18] (rekombinant, adjuveret, adsorberet).
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)
Human relevans af neoplastiske fund set i mus (rasH2 transgene) og karcinogenicitetsstudier i rotter efter behandling med sunitinib er uklar.
The relevance to humans of the neoplastic findings observed in the mouse (rasH2 transgenic) and rat carcinogenicity studies with sunitinib treatment is unclear.
Human rotavirus RIX4414 stamme (levende, svækket) ikke mindre end 106.0 CCID50
Human rotavirus RIX4414 strain (live, attenuated) not less than 106.0 CCID50
Human rotavirus RIX4414 stamme (levende, svækket)* ikke mindre end 106,0 CCID50
Human rotavirus RIX4414 strain (live, attenuated)* not less than 106.0 CCID50
Human rotavirus RIX4414 stamme (levende, svækket)* ikke mindre end 106.0 CCID50
Human rotavirus RIX4414 strain (live, attenuated)* not less than 106.0 CCID50
Human serumalbumin, dimethylsulfoxid, natriumchlorid.
Human serum albumine, dimethyl sulphoxide, sodium chloride.
Human von Willebrands faktor
Human von Willebrand factor
Humane anti-murine antistoffer
Human anti-murine antibodies
Humane hovedmetabolitter er N-3,5-dimethyl-gludantan, den isomeriske blanding af 4 - og 6-hydroxy-memantin og 1-nitroso-3,5-dimethyl-adamantan.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxy- memantine, and 1-nitroso-3,5-dimethyl-adamantane.
Humane hovedmetabolitter er N-3,5-dimethyl-gludantan, den isomeriske blanding af 4- og 6-hydroxy-memantin og 1-nitroso-3,5-dimethyl-adamantan.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4- and 6-hydroxy- memantine, and 1-nitroso-3,5-dimethyl-adamantane.
Humane hovedmetabolitter er N-3,5-dimethyl-gludantan, den isomeriske blanding af 4- og 6-hydroxy-memantin og 1-nitroso-3,5-dimethyl-adamantan.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6- hydroxy-memantine, and 1-nitroso-3,5-dimethyl-adamantane.
Humane hovedmetabolitter er N-3,5-dimethyl-gludantan, den isomeriske blanding af 4- og 6-hydroxy-memantin og 1-nitroso-3,5-dimethyl-adamantan.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxy- memantine, and 1-nitroso-3,5-dimethyl-adamantane.
Humane mikrosomale in vitro-studier og in vivo- studier tyder på, at enfuvirtid ikke hæmmer CYP450-enzymer.
In vitro human microsomal studies and in in vivo studies indicate that enfuvirtide is not an inhibitor of CYP450 enzymes.
Humanstudier med interaktionen mellem safinamid og CYP1A2 og CYP3A4-substrater (koffein og midazolam), viste ingen klinisk signifikant effekt på safinamids farmakologiske profil.
Human studies evaluating the interaction of safinamide with CYP1A2 and CYP3A4 substrates (caffeine and midazolam), did not demonstrate any clinically significant effects on the pharmacokinetic profile of safinamide.
Humant albumin Natriumklorid
Human albumin Sodium chloride
Humant fibrinogen (8,1 mg/cm2)
Human fibrinogen (8.1 mg/cm2)
Humant fibrinogen 79 mg/g Humant thrombin 726 IE/g
human fibrinogen 79 mg/g human thrombin 726 IU/g
Humant fibrinogen 8,1 mg
Human Fibrinogen 8.1 mg
Humant fibrinogen og Humant trombin: Omrix Biopharmaceuticals Ltd.
Human Fibrinogen and Human Thrombin: Omrix Biopharmaceuticals Ltd.
Humant fibrinogen, humant thrombin
Human Fibrinogen / Human Thrombin
Humant fibrinogen/humant thrombin
Human fibrinogen/ Human thrombin
Humant fibrinogen/humant thrombin
Human fibrinogen/Human thrombin
Humant hepatitis B-immunglobulin Subkutan anvendelse
Human hepatitis B immunoglobulin Subcutaneous use
Humant hepatitis B-immunglobulin til intramuskulær anvendelse er biotilgængeligt i recipientens kredsløb efter en forsinkelse på 2-3 dage.
Human hepatitis B immunoglobulin for intramuscular use is bioavailable in the recipient’s circulation after a delay of 2 – 3 days.
Humant IgG1ĸ monoklonalt antistof fremstillet ved rekombinant DNA-teknologi i en murin hybridom cellelinje.
Human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology.
Humant IgG4 passerer placentabarrieren, og nivolumab er et IgG4; nivolumab har derfor potentiale til at blive overført fra moderen til fosteret.
Human IgG4 is known to cross the placental barrier and nivolumab is an IgG4; therefore nivolumab has the potential to be transmitted from the mother to the developing foetus.
Humant insulin
Insulin human
Humant insulin fremskynder ligeledes optagelsen af aminosyrer i cellerne samt fremskynder proteinsyntesen og øger kaliumoptagelsen i cellerne.
It also promotes the uptake of amino acids into cells and promotes protein synthesis and enhances the uptake of potassium into cells.
Humant insulin s.c.
Insulin human SC use
Humant insulin s.c., i.v.
Insulin human SC, IV use
Humant koagulerbart protein indeholdende hovedsageligt fibrinogen og fibronektin *
Human clottable protein containing mainly fibrinogen and fibronectin
Humant normalt immunglobulin (immunoglobulinum humanum normale) (SCIg) En ml indeholder:
Human normal immunoglobulin (SCIg) One ml contains:
Humant normalt immunglobulin (IVIg) 1 ml indeholder:
Human normal immunoglobulin (IVIg) One ml contains:
Humant normalt immunglobulin (IVIg) En ml indeholder:
Human normal immunoglobulin (IVIg) One ml contains:
Humant normalt immunglobulin (IVIg)* En ml indeholder:
Human normal immunoglobulin (IVIg)* One ml contains:
Humant normalt immunglobulin (SCIg = subkutant immunglobulin)
Human normal immunoglobulin (SCIg = Subcutaneous Immunoglobulin)
Humant normalt immunglobulin 10 %
Human normal immunoglobulin 10
Humant normalt immunglobulin 10 % skal være klart og farveløst eller svagt gul.
The human normal immunoglobulin 10% should be clear and colourless or pale yellow.
Humant normalt immunglobulin 100 mg (renhed på mindst 98 % IgG)
Human normal immunoglobulin...................100 mg (purity of at least 98% IgG)
Humant normalt immunglobulin 100 mg.
Human normal immunoglobulin 100 mg.
Humant normalt immunglobulin er efter intravenøs indgivelse øjeblikkeligt og fuldstændigt biotilgængeligt i modtagerens kredsløb.
Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration.
Humant normalt immunglobulin100 mg IgG-renhed .............................. ≥ 98 %
Human normal immunoglobulin 100 mg IgG purity ................................. ≥ 98
Humant papillomvirus1 type 16 L1-protein2,3,4 20 mikrogram
Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms
Humant papillomvirus1 type 18 L1-protein2,3,4 20 mikrogram
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms
Humant plasmaprotein ..................................................................................................................
Human plasma protein...................................................................................................................
Humant protein 150 mg, hvoraf mindst 96 % er IgG, med et indhold af antistoffer mod hepatitis B- virus overfladeantigen (HBs) på 500 IE.
Human protein 150 mg of which at least 96 % is IgG, with a content of antibodies to hepatitis B virus surface antigen (HBs) of 500 IU.
Humant protein 150 mg/ml, hvoraf mindst 96 % er IgG, med et indhold af antistoffer mod hepatitis B- virus-overfladeantigen (HBs) på 500 IE/ml.
Human protein 150 mg/ml of which at least 96 % is IgG, with a content of antibodies to hepatitis B virus surface antigen (HBs) of 500 IU/ml.
Humant protein, 100 mg/ml, mindst 98 % er IgG
Human protein, 100 mg/ml, at least 98% is IgG.
Humant serumalbumin Dinatriumphosphat Natriumdihydrogenphosphat Natriumchlorid
Human serum albumin Dibasic sodium phosphate Monobasic sodium phosphate Sodium chloride
Humant serumalbumin Vand til injektionsvæsker
Human serum albumin Water for injections
Humant serumalbumin, dimethylsulfoxid, natriumchlorid.
Human serum albumine, dimethyl sulphoxide, sodium chloride.
Humant serumalbumin, natriumchlorid, natriumhydrogenfosfat og natriumdihydrogenfosfat.
Human serum albumin, sodium chloride, di- and monobasic sodium phosphate.
Humant thrombin (40 IE/ cm2)
Human thrombin (40 IU/ cm2)
Humant trombin
Human thrombin
Humant trombin 40 IE
Human Thrombin 40 IU
Humant trombin:
Human thrombin:
HUMENZA anbefales ikke til børn under 6 måneder.
HUMENZA is not recommended in children below 6 months of age.
HUMENZA består af 2 forskellige hætteglas:
HUMENZA consists of 2 separate vials:
HUMENZA består af 2 særskilte hætteglas:
HUMENZA consists of 2 separate vials:
HUMENZA består af to hætteglas: Det ene glas indeholder antigen (suspension), og det andet glas indeholder adjuvans (emulsion), som blandes inden indgivelse.
HUMENZA consists of two vials: one vial containing the antigen (suspension) and one vial containing the adjuvant (emulsion), which are mixed prior to administration.
Humenza er blevet godkendt under særlige omstændigheder.
Humenza has been given ‘Conditional Approval’.
Humenza er en vaccine til beskyttelse mod ”pandemisk” influenza.
Humenza is a vaccine to protect against ‘pandemic’ flu.
Humenza indeholder en influenzastamme kaldet A/California/7/2009 (H1N1)- lignende stamme (NYMC X-179A).
Humenza contains a flu strain called A/California/7/2009 (H1N1)-like strain (NYMC X-179A).
HUMENZA skal opbevares i køleskab (2° C – 8° C) og anvendes inden for 24 timer.
HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 hours
HUMENZA Suspension og emulsion til injektionsvæske, emulsion
HUMENZA Suspension and emulsion for emulsion for injection
HUMENZA suspension og emulsion til injektionsvæske, emulsion Pandemisk influenzavaccine (H1N1) (split virion, inaktiveret, adjuveret)
HUMENZA suspension and emulsion for emulsion for injection Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
HUMENZA’s evne til at beskytte fritter mod infektion i lungerne efter administration af en eller to doser blev vurderet.
The ability of one or two administrations of HUMENZA to protect ferrets against infection in the lungs was evaluated.
humerus, ribben og bækken)
ribs and pelvis)
Humira 0,8mg/kg hver anden uge
Humira 0.8mg/kg eow N=38
Humira 40 mg hver anden uge blev undersøgt hos patienter med moderat til alvorlig aktiv psoriasisartrit i to placebokontrollerede studier, PsA-I og PsA-II.
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA I and II.
Humira 40 mg hver anden uge blev undersøgt i to randomiserede, 24 ugers dobbelt-blinde placebo- kontrollerede studier med 393 patienter med aktiv ankyloserende spondylitis (gennemsnits score ved baseline for sygdomsaktivitet [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] var 6,3 i alle grupper), som ikke havde responderet tilstrækkeligt på konventionel behandling.
Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Humira 40 mg hver anden uge er vurderet hos 185 patienter i et randomiseret, 12 ugers dobbeltblindet, placebokontrolleret studie hos patienter med aktiv non-radiografisk aksial spondyloartitis (gennemsnitlig baseline score for sygdomsaktivitet [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] var 6,4 for patienter i behandling med Humira og 6,5 for patienter i placebo-armen), som havde haft utilstrækkeligt respons på eller var intolerante over for  1 NSAID eller havde en kontraindikation mod NSAID.
Humira 40 mg every other week was assessed in 185 patients in one randomised, 12 week double - blind, placebo - controlled study in patients with active non-radiographic axial spondyloarthitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance to  1 NSAIDs, or a contraindication for NSAIDs.